Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907855 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL6876401 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL6758987 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL6758990 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL13818211 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL15270499 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL15289517 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL2209386 | 0.80 | TDP1 (0.50) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL16699842 | 0.80 | FABP7 (0.48) | ALDH1A1HPGDTSHRFABP7FABP5 | |
| SCHEMBL28378581 | 0.79 | BACE1 (0.50) | ALDH1A1HPGDTSHRFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4135843-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115427110-A | Pyrazolo [1,5-D ] [1,2,4] triazine-5 (4H) acetamide as an NLRP3 inflammatory pathway inhibitor | 詹森药业有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | ALDH1A1 1603/4885HPGD 757/4885TSHR 4236/4885 |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | ALDH1A1 268/4885HPGD 116/4885TSHR 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.